Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Nektar Therapeutics

+ Add to Watchlist

NKTR:US

11.4800 USD 0.0200 0.17%

As of 20:10:00 ET on 06/01/2015.

Snapshot for Nektar Therapeutics (NKTR)

Open: 11.5200 Day's Range: 11.4650 - 11.7300 Volume: 1,032,424
Previous Close: 11.5000 52wk Range: 9.5100 - 17.5300 1-Yr Rtn: -0.43%

Stock Chart for NKTR

No chart data available.
  • NKTR:US 11.4900
  • 1D
  • 1M
  • 1Y
11.5000
Interactive NKTR Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for NKTR

Current P/E Ratio (ttm) 67.5294
Estimated P/E(12/2015) -
Relative P/E vs. SPX 3.6295
Earnings Per Share (USD) (ttm) 0.1700
Est. EPS (USD) (12/2015) -0.5050
Est. PEG Ratio -
Market Cap (M USD) 1,509.92
Shares Outstanding (M) 131.53
30 Day Average Volume 1,625,031
Price/Book (mrq) 19.5208
Price/Sale (ttm) 5.1114
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 07/31/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for NKTR

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for NKTR

Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. The Company's product pipeline is comprised of early to late stage drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology.

Howard W RobinPresident/CEOJohn L NicholsonSenior VP/CFO
Stephen K DobersteinSenior VP/Chief Scientific OfcrGil M LabrucherieSenior VP/Secy/Gen Counsel
More Company Profile & Key Executives for NKTR

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil